PNM Resources, Inc. (PNM - Free Report) is scheduled to release third-quarter 2019 earnings on Nov 1, before the opening bell.
Notably, the company delivered an average positive earnings surprise of 9.93% in the last four quarters.
What Our Quantitative Model Predicts
Our proven model predicts an earnings beat for PNM Resources this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. You can see the complete list of today’s Zacks #1 Rank stocks here.
Earnings ESP: The company’s Earnings ESP is +1.99%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Currently, PNM Resources carries a Zacks Rank #2.
Factors to Consider
In its second-quarter earnings call, the company announced that its financial performance was hurt by milder-than-expected weather. Nevertheless, a normal weather condition in July is likely to have made a positive impact on the company’s third-quarter results.
The company witnesses strong demand from its Texas-New Mexico Power Company (TNMP) customers, which has likely contributed to third-quarter performance.
The Zacks Consensus Estimate for third-quarter earnings per share is pegged at $1.26, which calls for year-over-year growth of 16.67%.
Other Stocks to Consider
Investors can consider the following players from the same industry that also have the right combination of elements to post an earnings beat in the to-be-reported quarter.
Eversource Energy (ES - Free Report) is slated to release third-quarter 2019 results on Nov 6. It has an Earnings ESP of +1.06% and a Zacks Rank #2.
Exelon Corporation (EXC - Free Report) is set to release third-quarter 2019 numbers on Oct 31. It has an Earnings ESP of +0.06% and carries a Zacks Rank #3.
PPL Corporation (PPL - Free Report) is scheduled to release third-quarter 2019 results on Nov 5. It has an Earnings ESP of +1.37% and a Zacks Rank #3.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>